April 30 (Reuters) - British drugmaker GSK said

it was "well positioned" to respond to any potential impact from

sector-specific tariffs if they were implemented and it had

identified options within its supply chain and productivity

initiatives to mitigate any hit.

U.S. President Donald Trump this month reiterated plans for

a "major" tariff on pharmaceutical imports, but he has not said

when and by how much he plans to raise levies on pharmaceutical

imports which could threaten an interwoven global supply chain

and raise U.S. drug costs by $51 billion annually.

Still, GSK reaffirmed its 2025 forecasts on Wednesday after

higher first-quarter turnover of 7.52 billion pounds ($10.07

billion) and core profit of 44.9 pence per share surpassed

analysts' expectations.

It was not immediately clear whether the drugmaker's outlook

had factored in the impact from tariffs and the company did not

give further details on the options identified.

In February, GSK had lifted its long-term sales target to

over 40 billion pounds by 2031, but uncertainties around U.S.

tariffs on pharmaceutical imports and the Trump administration's

policies on vaccines and HIV prevention loom large on drugmakers

in the near term.

($1 = 0.7468 pounds)